MedPath

James Felker

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:1

Trial Phases

2 Phases

Phase 1:2
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (66.7%)
Phase 2
1 (33.3%)

A Vaccine Trial for Low Grade Gliomas

Phase 2
Recruiting
Conditions
Low Grade Glioma
First Posted Date
2015-02-06
Last Posted Date
2025-01-06
Lead Sponsor
James Felker
Target Recruit Count
25
Registration Number
NCT02358187
Locations
🇺🇸

Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides with Imiquimod

Phase 1
Recruiting
Conditions
Ependymoma
Interventions
Biological: HLA-A2 restricted synthetic tumor antigen
Other: enzyme-linked immunosorbent assay
Other: flow cytometry
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
First Posted Date
2013-02-20
Last Posted Date
2024-12-06
Lead Sponsor
James Felker
Target Recruit Count
24
Registration Number
NCT01795313
Locations
🇺🇸

Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas

Phase 1
Completed
Conditions
Newly Diagnosed Pediatric Pontine Glioma
Newly Diagnosed Pediatric High Grade Glioma
Recurrent Pediatric Low Grade Glioma
Recurrent Pediatric High Grade Glioma
Interventions
Biological: HLA-A2 restricted glioma antigen peptides vaccine
First Posted Date
2010-05-25
Last Posted Date
2024-12-06
Lead Sponsor
James Felker
Target Recruit Count
60
Registration Number
NCT01130077
Locations
🇺🇸

Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.